- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Vaidya Sane Ayurved Laboratories Limited reported financial results for H1 FY25, showcasing revenue from operations of ₹41.80 crore, down 18.2% from ₹51.10 crore in H1 FY24. However, EBITDA surged to ₹5.76 crore, marking a 115% increase driven by reduced employee costs and other expenses. The profit after tax also improved to ₹3.26 crore, up from ₹1.18 crore in the previous year, resulting in a basic EPS of ₹3.59.
The company is focusing on expanding its healthcare network, with plans to add 100 beds to its Khopoli hospital and increase bed capacity at the Nagpur hospital over the next 12 to 18 months. Madhavbaug aims to enhance accessibility to its services, particularly through cashless treatment options, with ambitions of establishing around 1,000 clinics and several hospitals by 2030.
The recent "Azadi Diabetes Se" campaign was notable, raising awareness around reversing Type 2 Diabetes via Ayurvedic treatments. Their commitment to integrating traditional medicine with modern diagnostics reflects a strategic growth direction, promising potential for continued business development. Investors should watch this transformation closely, as it highlights growth opportunities and the robustness of Madhavbaug’s operational model.
All announcements from Vaidya Sane Ayurved Laboratories Limited